Why new Alzheimer's drugs are in for a tepid launch  - MM+M - Medical Marketing and Media

Approval and coverage hurdles are falling, yet diagnostic requirements and data collection will temper drugs' initial uptake, analysts say.

Related Keywords

,Eli Lilly ,Chris Schott ,Jenifer Ehreth ,Salveen Richter ,America Ph ,Marc Goodman ,Deborah Williams ,Masoud Toloue ,Drug Administration ,Goldman Sachs ,Centers For Medicare ,International Market Access ,Medicaid Services ,Alliance For ,Alzheimer Association ,Health Policy Insights ,Sue Peschin ,Chiquita Brooks Lasure ,Pharmaceutical Researchers ,